Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

New Products In Brief

This article was originally published in The Gray Sheet

  • News

Executive Summary

Mela Sciences launches MelaFind melanoma detection device in the U.S. Medtronic launches CapSure Sense MRI SureScan pacing leads overseas. More product news.

You may also be interested in...



MelaFind PMA Approval Sets Stage For Early 2012 Debut

New Products In Brief

Sonitus’ SoundBite gains second FDA OK

Medtronic Revo MRI Pacer Approved, But Still Faces Reimbursement Hurdle

Medtronic is hoping that the immediate U.S. launch of its newly approved Revo MRI SureScan MRI-compatible pacemaker will help boost market share in the device category, but magnetic resonance imaging scans of implant recipients still face a key reimbursement hurdle.

Table

View full table

Related Content

Medtech Insight

Topics

Related Companies

Tags:
Medical Device
Latest Headlines

‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports

Behavioral Health Company Two Chairs Secures $72M In Equity And Debt Infusion

Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations

Israeli Company Lands De Novo Clearance For Digital Bone Marrow Application

See All
UsernamePublicRestriction

Register

MT031041

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By